A Phase lb/ll, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 11 Nov 2021
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Venetoclax (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms VICKI
- Sponsors Roche
Most Recent Events
- 12 Mar 2021 Status changed from active, no longer recruiting to discontinued based on broader development and strategic prioritisation. The sponsor concluded there is no benefit-risk impact on the CO41863 study.
- 11 Dec 2020 Trial design presented at the 43rd Annual San Antonio Breast Cancer Symposium.
- 26 Oct 2020 Status changed from recruiting to active, no longer recruiting.